Member Info for inanaco

yes the Glycans Mr BillBrown will be fascinating how it develops and indeed how far Scancell has gone on other discoveries in that area, you will find a time lag from discovery to RNS of anything up to a year or more as the Patent system is so slow, and scancell rarely release any info before publication ..

maybe ... but he fully understands the concept of the immune system ... immune surveillance .. and the importance of all arms of the immune system working in concert ... and the proof of the power of a vaccine especially the platform ie the way it engages the immune system has a direct correlation of its potency

Immunobody bypasses the innate and goes direct to adaptive ... many don't they need the innate to instigate the adaptive and because you are not giving whole virus the innate response to adaptive response is proportional to whats given ....and because we are direct to adaptive we are also controlling the T cell polarization and avidity ....

the damage done by the Ichor gun is an adjuvant .. i would love to know how lindy with SCIB2 has circumvented that adjuvant effect with SCIB2 by other delivery methods ... maybe Burble can have an input on that ...

In vivo electroporation (EP) is used to enhance the uptake of nucleic acids and its association with DNA vaccination greatly stimulates immune responses to vaccine antigens delivered through the skin. However, the effect of EP on cutaneous cell behavior, the dynamics of immune cell recruitment and local inflammatory factors, have not been fully described. Here, we show that intradermal DNA vaccination combined with EP extends antigen expression to the epidermis and the subcutaneous skin muscle in non-human primates. In vivo fibered confocal microscopy and dynamic ex vivo imaging revealed that EP promotes the mobility of Langerhans cells (LC) and their interactions with transfected cells prior to their migration from the epidermis. At the peak of vaccine expression, we detected antigen in damaged keratinocyte areas in the epidermis and we characterized recruited immune cells in the skin, the hypodermis and the subcutaneous muscle. EP alone was sufficient to induce the production of pro-inflammatory cytokines in the skin and significantly increased local concentrations of Transforming Growth Factor (TGF)-alpha and IL-12. Our results show the kinetics of inflammatory processes in response to EP of the skin, and reveal its potential as a vaccine adjuvant.

https://www.nature.com/articles/s41598-017-04547-2

another point some of the work is being done by the consortium ... they do not have to provide that information to Scancell shareholders ... so just like CRUK .. they have no responsibility to keep us informed

because the vaccine (covid) is funded many process will be ongoing and over lapping for speed, so like others have done the pre clinical data might not be prepared and released for peer review until the trial is actually underway which is what we have seen in other covid trials ... so you may feel neglected by Scancell, but that is because speed of delivery over rides standard protocol .......... and should not be seen as a negative

scancell has not released any data yet and has no clinical data to consider ...

we know the principle of the vaccine and its targets .. and possibly the way it will be delivered ... but that is as far as we have been advised Via RNS

has he endorsed any vaccine .......... ?

but he has endorsed Moditope ... indeed he was a guest speaker at the moditope presentation

nvestor Day Agenda - Scancellwww.scancell.co.uk › investor-day-agenda
Investor Day Agenda ... Led by Prof Karol Sikora, Dean of Medicine , University of Buckingham; Honorary Consultant Oncologist at Hammersmith Hospital.

that is why "toxicology" is a major hurdle to over come on the pre-clinical trial route

Moditope i believe has cleared that hurdle

this is why the Karolinska Institutet being involved with Moditope plays such a significant role because of its understanding of immune system Dysregulation caused by autoimmune and specifically citrullination .. they also hold the patent for enolase in this regard .. indeed they gave us the rights to it for cancer which we subsequently patented

I would add the patent covers only cancer and we are actively targeting the immune system against autophagy in cancer rather than trying to suppress it like you would in RA or as you have mentioned Alzheimer's , does the construct of the brain include vimentin ? or are you considering Plaques. Inflammation of the brain caused by Alzheimer i would suspect would render the patient not suitable for any cancer treatment especially a late stage cancer treatment like Moditope ... so little risk i fear there of off target toxicity

On the patent thou this covers the construct ie the skeleton of immunobody, and the way immunobody engages the Dendritic cell is also including in the patent .. that is very important as that is what gives Immunobody "Cross presentation" this primes the T cell with multiple signals Keeps the T cell locked onto the Dendritic cell for longer which generates that High Avidity and that skeleton can carry many epitopes so the vaccine can also carry multiple targets and importantly both MHC1 and MHC11 which means both CD4 helper T cells and CD8 T ells are activated together

Good post Burble .. i will add "the Epitopes" although cancer has millions of them and you can whittle them down to find targets that the cancer over express they are rare and often do not cause a response from the immune system so the difficulty is finding targets ........ as Burble has posted that don't cause off target toxicity and are immunogenic, that is the major reason why other vaccines fail and because they don't elicit High Avidity T cells that are capable of suppressing the cancer suppression techniques .... in other words flip the environment to pro inflammatory

Immunobody has shown it can do this ......... so combining it with products that also act on that suppression ie PD-1 or CTl4
is what will generate "Synergy" which means the efficacy of the combo is higher than each on its own

hence the trial is with Keytruda (a checkpoint)

The industry is spending Billions in this area, so what ever checkpoint is developed it should be synergistic with Immunobody

"could be" .....

should be worth a good discussion ...

he was a very determined man .. and stated its a long haul from the start

thank you Ivy .. for that

thats him ... turns up chauffeur driven

same with me, wild emailed twice this year only

i have no idea who Lindy corresponds with, however the original 5 two of the investors knew lindy very well i think they got in from the start can't remember the names but one had 7,000,000 shares and probably still does .. as he has attended every AGM since

lol ...

only at the coffee machine ... after the Investor day i asked her for a quick chat .. and Lindy dragged me off for coffee i did not refuse